Therefore, our current work aimed to evaluate the role of HH-GLI and NOTCH signaling pathways as regulatory molecular mechanisms responsible for chemotherapy resistance in models of KRAS- or BRAF-driven CRC. The gene discussed is GLI1; the disease is colorectal carcinoma.